TCL Archive New benchmark for CCSG award funding will be lowered from 20 percent of NCI research base to 15 percent, the program’s “reality ratio,” Karen Antman tells NCAB. October 8, 2004
TCL Archive Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer November 28, 2014
TCL Archive Tissue of Origin Test Consistent With Diagnosis In Blinded Validation Study January 28, 2011
TCL Archive In Brief: Delores Esparza President Elect Of ONS; Brown Demands Jako Retract “Insulting Remarks” May 13, 1988
